8-K: BioNexus Gene Lab Corp. Announces 1-for-10 Reverse Stock Split to Regain NASDAQ Compliance

BioNexus Gene Lab Corp. will implement a 1-for-10 reverse stock split, effective April 7, 2025, to address its bid price deficiency and maintain its NASDAQ listing.

Summary

• BioNexus Gene Lab Corp.'s shareholders previously approved a reverse stock split.
• The Board of Directors ratified a 1-for-10 reverse stock split on March 19, 2025.
• The reverse stock split is effective at 12:01 a.m. Eastern Time on April 7, 2025.
• The company's stock will trade on a split-adjusted basis on the Nasdaq Capital Market under the ticker symbol BGLC on April 7, 2025.
• The company is undertaking the reverse stock split to cure its bid price deficiency under NASDAQ rules.
• To regain NASDAQ compliance, the company's closing bid price must be above $1.00 per share for 10 consecutive trading days during the compliance period, which ends May 1, 2025.
• The Articles of Amendment regarding the reverse stock split were filed with the Wyoming Secretary of State on April 1, 2025.
• The new CUSIP number for the company is 090628306, which was made eligible by DTCC on March 25, 2025.
• Every ten shares of issued and outstanding common stock will automatically be converted into one share of common stock.
• Shareholders who would otherwise be entitled to receive a fractional share will receive a cash payment based on the closing price of the company's common stock on The Nasdaq Capital Market on April 4, 2025.
• Securities Transfer Corporation will act as the exchange agent for the reverse split.
• The reverse stock split will not affect any shareholder's percentage ownership interest or proportional voting power, subject to the treatment of fractional shares.

Sentiment

Score: 5

Explanation: The announcement is neutral. While the reverse stock split aims to address a negative situation (bid price deficiency), it is a common corporate action.

Positives

• The reverse stock split aims to regain NASDAQ compliance, which could improve investor confidence.
• The company is addressing its bid price deficiency proactively.

Negatives

• The reverse stock split is a consequence of the company's failure to maintain a minimum bid price of $1.00 per share.
• Reverse stock splits can sometimes be perceived negatively by investors.

Risks

• There is no guarantee that the reverse stock split will successfully increase the stock price and maintain NASDAQ compliance.
• The company must achieve a closing bid price above $1.00 per share for 10 consecutive trading days before May 1, 2025, to avoid delisting.

Future Outlook

The company hopes that the reverse stock split will increase its stock price and allow it to regain compliance with NASDAQ listing requirements.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. Other companies in similar situations may consider this approach.

Comparison to Industry Standards

• Many companies facing NASDAQ compliance issues have implemented reverse stock splits, including companies such as [Comparable Company 1] and [Comparable Company 2].
• The success of a reverse stock split depends on various factors, including investor sentiment and the company's underlying financial performance.
• Some companies have successfully regained compliance through reverse stock splits, while others have ultimately been delisted.

Stakeholder Impact

• Shareholders will see their shareholdings adjusted to reflect the 1-for-10 reverse stock split.
• Shareholders who would otherwise be entitled to receive a fractional share will receive a cash payment.
• The company hopes to maintain its NASDAQ listing, which could benefit shareholders.

Next Steps

• Implementation of the reverse stock split on April 7, 2025.
• Monitoring of the stock price to ensure compliance with NASDAQ requirements.
• Shareholders holding physical certificates will receive instructions for exchanging their certificates from the exchange agent.

Key Dates

Keywords

reverse stock split, NASDAQ compliance, bid price deficiency, BGLC, BioNexus Gene Lab Corp., stock split